TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01630252
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGL5001 matching placebo (twice a day) for 8 weeks + one unique DMPA 150 mg injection
Study: NCT01630252
Drug: PGL5001
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGL5001 320mg/day (160 mg twice a day) for 20 weeks + DMPA 150mg injection. Second DMPA injection between 85 to 89 days after first injection
Study: NCT01630252
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGL5001 matching placebo (twice a day) for 20 weeks + DMPA 150mg injection. Second DMPA injection between 85 to 89 days after first injection
Study: NCT02370485
Drug: LY2801653
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00700544
Drug: chemotherapy treatment (see arms)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy + maintenance chemotherapy
Study: NCT00964912
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Solution, Oral, 0 mg, single dose, one dose
Study: NCT02091531
Drug: MLN0128
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04142424
Drug: AZD2693
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive SC injection of AZD2693 as per the arms they are randomized.
Study: NCT04142424
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive SC injection of placebo matched to AZD2693, as per the arms they are randomized.
Study: NCT02202213
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02856243
Drug: new antiviral therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00408863
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06454825
Drug: Intravenous drug
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: medications were applied intravenously to the groups 30 minutes before end of the procedure
Study: NCT03532854
Drug: Ezetimibe/Rosuvastatin
Normalized name: EZETIMIBE/ROSUVASTATIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe/Rosuvastatin P.O
Study: NCT03020134
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00146809
Drug: Minocyline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00017654
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02696733
Drug: 0.9% Natrium Chloratum with a 2nd generation cephalosporin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00580034
Drug: Campath Purged Non-myeloablative ASCT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparative regimen: Begins on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours.~Patient Evaluation: Will occur 2-3 times per week by physical exam for toxicity through day 45.
Study: NCT01231542
Drug: GSK1349572
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1349572 is an experimental drug for the treatment of HIV. GSK1349572 is in the integrase inhibitor class. It is not yet approved by the FDA.
Study: NCT01648296
Drug: [18F]FluorbetaOx
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorine 18-labeled FluorbetaOx
Study: NCT00926731
Drug: AZD1152
Approvals — FDA: no, EMA: no, PMDA: no
Description: Variable dose via a 7-day continuous infusion
Study: NCT02594644
Drug: Aminolevulinic Acid
Normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levulan® Kerastick® DUSA Pharmaceuticals, Inc., Wilmington, MA
Study: NCT01121848
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form:vials of 50 mg/5 mL or 500 mg/50mL Route of administration: IV~Dose regimen:
Study: NCT00621556
Drug: RG1068 (Synthetic Human Secretin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
Study: NCT03162510
Drug: LV
Normalized name: VALVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: LV 30mg twice daily from D1 to D7, every 14 days as a cycle till disease progression
Study: NCT00822705
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control arm
Study: NCT02359357
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00616382
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV indomethacin starting at a dose of 0.4 mg/kg given over 30 minutes, increased daily by increments of 0.2 mg/kg/dose and given at intervals of 12 hours until a maximum dose of 1 mg/kg is reached, or until a total indomethacin dose of 6 mg/kg has been given. Daily echocardiography will be performed to monitor the progress of ductal closure. Once echocardiographic evidence of a closed ductus is achieved, two additional doses indomethacin will be given 24 hours and 48 hours later, using the same dose used in the last indomethacin infusion.
Study: NCT01599507
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIW dosing, capsule
Study: NCT02068690
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02232581
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02704702
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02704702
Drug: Fimasartan + Rosuvastatin
Normalized name: rosuvastatin and fimasartan
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00258765
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00936533
Drug: Dysport® (Botulinumtoxin A (Btx A))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection in patients´ soles with Btx A in one foot and sodium chloride in the other, with the possibility of a second injection after 12 weeks. The drug will be given in general anaesthesia after curettage of the focal hyperkeratoses. Only the areas with focal hyperkeratoses will be injected with 50 ul per injection.The active drug Btx A (Dysport®, solution for injection) has a concentration of 100 U/ml, and the maximum dose is 300 U per foot.
Study: NCT00936533
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo preparation without active compound, administered as the active drug.
Study: NCT01265563
Drug: N-acetylcysteine placebo and silibin placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary Supplement: N-acetylcysteine placebo excipient and silibin placebo orally twice daily for three months
Study: NCT01265563
Drug: N-acetylcysteine active and silibin placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin placebo orally twice a day for three months
Study: NCT01265563
Drug: N-acetylcysteine placebo and silibin active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary Supplement: silibin 480 mg orally twice daily and N-acetylcysteine placebo orally twice a day for three months
Study: NCT01265563
Drug: N-acetylcysteine active and silibin active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin 480 mg orally twice daily for three months
Study: NCT01265563
Drug: N-acetylcysteine active + high-dose silibin active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin 960 mg orally twice daily for three months
Study: NCT02013167
Drug: Standard of Care Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: * FLAG (fludarabine, cytarabine arabinoside, and granulocyte colony-stimulating factor) ± anthracycline-based regimen (e.g. idarubicin 10 mg/m² days 1 \& 3; fludarabine 30 mg/m² days 1-5; cytarabine arabinoside 2 g/m² days 1-5). Patients \> 60 years: Idarubicin 5 mg/m² day 1 \& 3; fludarabine 20 mg/m² day 1-5; cytarabine arabinoside 1 g/m² day 1-5~* HiDAC (high-dose cytarabine arabinoside) - based regimen ≥1 g/m²/day ± anthracycline and/or in combination with other drugs such as native Escherichia coli asparaginase, polyethylene glycol linked to asparaginase (PEG-asparaginase), vinca alkaloids, steroids, etoposide or alkylating agents~* High-dose methotrexate-based regimen (HDMTX; 500 mg/m² to 3 g/m² infused up to 24 hours) in combination with native E. coli asparaginase, PEG-asparaginase, vinca alkaloids, steroids, etoposide or alkylating agents.~* Clofarabine as a single agent as recommended in the prescribing information or clofarabine-based regimens with 20 mg/m²/day for up to 5 days.
Study: NCT04120753
Drug: OLOMAX 20/5/5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, QD
Study: NCT04120753
Drug: OLOMAX 20/5/10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, QD
Study: NCT05594017
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient receives a dose of saline via IV fifteen minutes prior to spatial or episodic memory task/completion.
Study: NCT02734771
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02734771
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01345968
Drug: Ferinject 50 mg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv administration of max. 50 ml (Dilution: 20 ml in 30 ml NaCl 0.9%) in 30 minutes
Study: NCT01345968
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv administration of max. 50 ml in 30 minutes
Study: NCT02146638
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02142322
Drug: MODIFIED FOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified FOLFOX6 regimen consists of oxaliplatin 100 mg/m2 and FA 100 mg/m2 given as a 2 hour intravenous infusion, followed by 5-FU 2.4 g/m2 given as a continuous infusion over 46 hour, repeated every 2 weeks. Patients receive 4 cycles of neoadjuvant modified FOLFOX6 followed by curative radical surgery with D2 dissection and 4 cycles of adjuvant modified FOLFOX6.
Study: NCT01005316
Drug: Induction Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Per standard of care guidelines for immunosuppression at each clinical site.
Study: NCT01005316
Drug: Immunoglobulins, Intravenous
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-transplant course of intravenous immunoglobulin therapy per standard of care guidelines for immunosuppression at each clinical site.
Study: NCT04313374
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: the PCA will contain placebo
Study: NCT00370760
Drug: oral colchicine, dexamethasone, low molecular weight heparin, 5-FU
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00370760
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04329390
Drug: Anticoagulant drugs
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription of, or already on oral anticoagulant treatment.
Study: NCT02130687
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive two capsules of placebo to preserve the blinding of the study.~In a separate period, subjects will receive one capsule of placebo and one capsule of sitagliptin.
Study: NCT03397082
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mL of sterile gel applied topically to cervix previous to clamping and paracervical blockade.
Study: NCT00625196
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be supplied as dry powder inhaler.
Study: NCT03214627
Drug: IV iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV iron given monthly as required - dose determined by the ACM and as agreed by the investigator
Study: NCT00873041
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplied as matching 125 mg, 250 mg and 500 mg tablets.
Study: NCT03214627
Drug: Erythropoiesis-Stimulating Agent (ESA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESA given monthly as required over 6 months - dose determined by the ACM and as agreed by the investigator
Study: NCT04616183
Drug: ERK1/2 Inhibitor LY3214996
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01007435
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Initially, patients received methotrexate 7.5 mg (3, 2.5 mg tablets) orally once a week. If a patient had swollen or tender joints, the dose was increased to 15 mg and 20 mg weekly, at the Week 4 and Week 8 visits, respectively.
Study: NCT01007435
Drug: Placebo to methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received placebo to methotrexate orally once a week.
Study: NCT01257230
Drug: placebo Respimat
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo representing comparator
Study: NCT00974441
Drug: Depakote®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg Extended Release Tablet
Study: NCT01536665
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously (s.c., under the skin) once daily for 4 weeks.
Study: NCT02209545
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 patients undergoing abdominal myomectomy operation will receive two tablets of Vitamin B6 (100mg) buccally one hour before the operation.
Study: NCT00322023
Drug: D-serine
Normalized name: D-Serine
DrugBank: D-Serine (DB03929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-serine at following dose levels: 30 mg/kg, 60 mg/kg, and 120 mg/kg. PK/PD studies done at day 1. Medication will be administered as powder dissolved in liquid given in two divided doses daily for 4 weeks.
Study: NCT00322023
Drug: D-serine
Normalized name: D-Serine
DrugBank: D-Serine (DB03929)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04071262
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01320553
Drug: SPARC1102 II
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPARC1102 II will be administered in both eyes
Study: NCT01320553
Drug: SPARC1102 III
Normalized name: CARDIOTOXIN III
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPARC1102 III will be administered in both eyes
Study: NCT01320553
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle will be administered in both eyes
Study: NCT02664649
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: VKA or Antiplatelet therapy
Study: NCT03319563
Drug: Local anesthetic-epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Bupivacaine 0.5% (Astra Zeneca) 2 mg/Kg.~* Lidocaine 5 mg/Kg.~* Epinephrine 5 mcg/ml of the total volume.~* Add normal saline to a total volume of 100 ml/10 cm of the wound length.
Study: NCT04044599
Drug: Gynoflor
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAGİNAL GYNOFLOR
Study: NCT03831191
Drug: LY3375880
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT03831191
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT01220973
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03645525
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline
Study: NCT03032783
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04345861
Drug: hydroxychloroquine + azithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination hydroxychloroquine : 800mg(Day1) then 600 mg (Day 2 to Day 11) Azithromycin 500mg (day 1) then 250 mg (Day 2 to Day 5)
Study: NCT05455918
Drug: TIP treatment (paclitaxel/ifosfamide/cisplatin)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel 240mg/m2/day D1 (total 240mg/m2) Ifosfamide 1.5g/m2/day D2\~5 (total 6g/m2) Cisplatin 25mg/m2/day D2\~5 (total 100mg/m2)
Study: NCT03311139
Drug: Antithrombotic agents
Normalized name: ANTITHROMBOTIC AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelets and anticoagulants purchased 4 months before and within 7 days after the index date
Study: NCT02185430
Drug: saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline infusion, bolus of 1.0 μg kg-1 over 10 min followed by a continuous infusion at 0.5 μg kg-1 h-1 infusion during one-lung ventilation, intravenous
Study: NCT00189332
Drug: 852A
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00527683
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: orange juice is administered twice daily in containers indistinguishable from the treatment arm.
Study: NCT00445211
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin administered at 500units/hour while on Intra-Aortic balloon Pump (IABP).
Study: NCT00002858
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002858
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00709293
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline will be utilized as a placebo comparator. It will be infused in the same fashion as the Thymoglobulin in the intervention arm.
Study: NCT01951339
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg placebo once daily
Study: NCT01951339
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg placebo once daily for three months
Study: NCT01129713
Drug: Secretol
Normalized name: gonorrheal urethral secretion human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparing 80/80 once daily to Nexium once daily in healing erosive esophagitis.
Study: NCT02276352
Drug: Treatment 1
Normalized name: CVS Acne Treatment 10% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02276352
Drug: Treatment 2
Normalized name: epoch Blemish Treatment 2 % Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04457609
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Current standardized treatment for Covid-19
Study: NCT00876850
Drug: PTK 0796
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTK 0796 100mg for injection; PTK 0796 tablet 150mg
Study: NCT00451867
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04049266
Drug: KSI-301
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal Injection
Study: NCT01517165
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01703208
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to omarigliptin capsule or tablet administered orally once weekly
Study: NCT02010333
Drug: Ha44 Gel 0.74% w/w
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA44 Gel 0.74% comprises of Abametapir as the active pharmaceutical ingredient and Benzyl Alcohol as one of the excipients.
Study: NCT01407471
Drug: Clobetasol + Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One application 6 days a week during 4 weeks
Study: NCT01407471
Drug: Placebo + Spironolactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: One application 6 days a week during 7 weeks
Study: NCT01407471
Drug: Placebo + Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One application 6 days a week during 7 weeks
Study: NCT01493102
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine will be reduced first (0.1 microgram/kg/hour)
Study: NCT03349216
Drug: Systemic Analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: in this group the patients will receive ketamine 1-2 mg/kg IV slow ( Bioniche,Ireland Ketamine Hydrochloride 500mg/10cc)and titrated to effect. again here the pain score will be assessed before procedure and after the procedure every 5 minutes until 30 minutes by NRS ( Numerical Rating Score)
Study: NCT01880749
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02511483
Drug: Placebo PO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets administered with the same schedule of Propranolol tablets
Study: NCT01335724
Drug: Diclofenac diethylamine 1.16% gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac diethylamine 1.16% gel
Study: NCT01335724
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel
Study: NCT04202224
Drug: Ibuprofen 400 mg and Acetaminophen 500 mg
Normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Analgesia.
Study: NCT01069159
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The protocol of the study requires that two doses of placebo be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Half of the subjects (33) will be randomized to receive placebo.
Study: NCT03484507
Drug: Prednisolone Sodium Phosphate
Normalized name: Prednisolone Sodium Phosphate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 drop 4 times daily for weeks 4-9, then 2 times daily for weeks 10-11
Study: NCT03484507
Drug: Prednisolone Sodium Phosphate
Normalized name: Prednisolone Sodium Phosphate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 drop 4 times daily for weeks 6-9, then 2 times daily for weeks 10-11
Study: NCT04270682
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adult cohort patients will receive blinded 250 mg CDCA TID or placebo during the double-blind periods based upon their treatment assignment.
Study: NCT04270682
Drug: CDCA Weight-Based Dose TID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the pediatric cohort will complete a weight-based dose titration to a tolerated dose and will maintain that tolerated dose for the remainder of the study. Pediatric cohort dosing of CDCA will not exceed an equivalent dose of 750 mg/day.